KCM
ALXN

Kames Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Kames Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-5,897
Closed -$978K – 190
2014
Q3 		$978K Sell
5,897
-905
-13% -$149K 0.03% 157
2014
Q2 		$1.06M Sell
6,802
-709
-9% -$112K 0.03% 147
2014
Q1 		$1.14M Sell
7,511
-2,394
-24% -$381K 0.04% 147
2013
Q4 		$1.32M Hold
9,905
– – 0.04% 145
2013
Q3 		$1.15M Buy
+9,905
New +$1.09M 0.04% 149

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Kames Capital Management's ALXN Position: Q4 2014 in Review

Kames Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2014, closing a stake of 5,897 shares — an estimated $978K sold.

Kames Capital Management first reported a position in ALXN in Q3 2013 and held it in 5 quarters. The position peaked at $1.32M in Q4 2013. 578 funds tracked by Wall St. Rank hold ALXN as of Q4 2014.

  • Kames Capital Management reported no remaining Alexion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Kames Capital Management sold 5,897 Alexion Pharmaceuticals shares in Q4 2014, an estimated $978K.
  • Kames Capital Management first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 5 quarters.
  • Kames Capital Management's Alexion Pharmaceuticals position peaked at $1.32M in Q4 2013.
  • 578 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2014.

Based on Kames Capital Management's 13F filing for Q4 2014, filed 3 Feb 2015.